|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2004-10-12
|
|
pubmed:abstractText |
Intravenous immunoglobulin (IVIg) has been reported to reduce disease activity in patients with relapsing-remitting multiple sclerosis. We assessed the effect of IVIg treatment in patients after the first neurological event suggestive of demyelinative disease and evaluated the occurrence of a second attack and dissemination in time demonstrated by brain magnetic resonance imaging within the first year from onset.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0003-9942
|
|
pubmed:author |
pubmed-author:AchironAnatA,
pubmed-author:BarakYoramY,
pubmed-author:DolevMarkM,
pubmed-author:FaibelMeirM,
pubmed-author:GurevichMM,
pubmed-author:KishnerIrenaI,
pubmed-author:LavieMorM,
pubmed-author:MagalashviliDavidD,
pubmed-author:RazHaviH,
pubmed-author:Sarova-PinhasIdaI,
pubmed-author:SternYaelY
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
61
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1515-20
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15477504-Adult,
pubmed-meshheading:15477504-Brain,
pubmed-meshheading:15477504-Demyelinating Diseases,
pubmed-meshheading:15477504-Dose-Response Relationship, Drug,
pubmed-meshheading:15477504-Double-Blind Method,
pubmed-meshheading:15477504-Drug Administration Schedule,
pubmed-meshheading:15477504-Female,
pubmed-meshheading:15477504-Gadolinium,
pubmed-meshheading:15477504-Humans,
pubmed-meshheading:15477504-Immunization, Passive,
pubmed-meshheading:15477504-Immunoglobulins, Intravenous,
pubmed-meshheading:15477504-Magnetic Resonance Imaging,
pubmed-meshheading:15477504-Male,
pubmed-meshheading:15477504-Middle Aged,
pubmed-meshheading:15477504-Multiple Sclerosis,
pubmed-meshheading:15477504-Odds Ratio,
pubmed-meshheading:15477504-Time Factors,
pubmed-meshheading:15477504-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.
|
|
pubmed:affiliation |
Multiple Sclerosis Center and Neuroradiology Unit, Sheba Medical Center, Tel-Hashomer 52621, Israel. achiron@post.tau.ac.il
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
